Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Women's Health Reviews
  4. Volume 21, Issue 2
  5. Article
Volume 21, Issue 2
  • ISSN: 1573-4048
  • E-ISSN: 1875-6581

Abstract

Background

Polycystic ovarian syndrome (PCOS) has emerged as one of the most common endocrine and metabolic disorders seen in women of childbearing age throughout the whole world. The complex pathophysiology, different diagnostic criteria, and various manifestations attached to several environmental factors, including lifestyle influences, have made it one of the most difficult disorders to treat in recent times. In addition, inadequate knowledge among patients and a lack of dedicated approved medications have only enhanced the difficulties in treating such a heterogeneous disorder.

Objective

The main objective of this review-type paper is to provide a detailed overview of PCOS along with the current concept of a clinical stance in this complex multigenic disorder.

Method

The following databases were used for literature searches: PubMed, Frontiers, Science Direct, Springer, Wiley, and MDPI. For the purpose of finding pertinent articles and contents, the keywords “PCOS; hirsutism; psychological burden; obesity” and others of a similar nature were utilized.

Conclusion

PCOS is a complicated hormonal, metabolic, and psychological condition with many different clinical manifestations. It is among the most prevalent causes of infertility. Before considering any medication choices, lifestyle modifications should be considered the primary therapeutic prescription for PCOS-related infertility. According to recent studies, PCOS does not affect the risk of ovarian or breast cancer, but it does raise the risk of endometrial cancer in women of all ages. These results suggest that PCOS may increase the risk of gynaecological cancer morbidity. The following stage is ovulation stimulation, which is best accomplished with letrozole and is followed by clomiphene citrate. Women who had not responded to the first-line oral ovulatory medicine were given gonadotropins as a backup. Early detection of girls with a high propensity to develop PCOS will be made possible by a comprehensive knowledge of the condition's etiology. Adolescent PCOS will be better managed overall, related comorbidities will be prevented, and quality of life will increase with customized therapeutic approaches.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cwhr/10.2174/0115734048268656231127064615
2024-01-16
2025-01-11

  • From This Site

    /content/journals/cwhr/10.2174/0115734048268656231127064615
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Hum. Reprod.2004191414710.1093/humrep/deh098
     [Google Scholar]
  2. MeloA.S. VieiraC.S. BarbieriM.A. Rosa-e-SilvaA.C.J.S. SilvaA.A.M. CardosoV.C. ReisR.M. FerrianiR.A. Silva-de-SáM.F. BettiolH. High prevalence of polycystic ovary syndrome in women born small for gestational age.Hum. Reprod.20102582124213110.1093/humrep/deq16220573680
     [Google Scholar]
  3. AzzizR. CarminaE. DewaillyD. Diamanti-KandarakisE. Escobar-MorrealeH.F. FutterweitW. JanssenO.E. LegroR.S. NormanR.J. TaylorA.E. WitchelS.F. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report.Fertil. Steril.200991245648810.1016/j.fertnstert.2008.06.03518950759
     [Google Scholar]
  4. SteinI.F. LeventhalM.L. Amenorrhea associated with bilateral polycystic ovaries.Am. J. Obstet. Gynecol.193529218119110.1016/S0002‑9378(15)30642‑6
     [Google Scholar]
  5. ICD-10. International Statistical Classification of Diseases and Related Health Problems.Available from:https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2010.pdf (Accessed on: 20.09).
  6. DokrasA. SainiS. Gibson-HelmM. SchulkinJ. CooneyL. TeedeH. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome.Fertil. Steril.2017107613801386.e110.1016/j.fertnstert.2017.04.01128483503
     [Google Scholar]
  7. RadoshL. Drug treatments for polycystic ovary syndrome.Am. Fam. Physician200979867167619405411
     [Google Scholar]
  8. WolfW. WattickR. KinkadeO. OlfertM. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity.Int. J. Environ. Res. Public Health20181511258910.3390/ijerph1511258930463276
     [Google Scholar]
  9. Bani MohammadM. Majdi SeghinsaraA. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH.Asian Pac. J. Cancer Prev.2017181172110.22034/apjcp.2017.18.1.1728240001
     [Google Scholar]
  10. WangR. MolB.W.J. The Rotterdam criteria for polycystic ovary syndrome: Evidence-based criteria?Hum. Reprod.201732226126410.1093/humrep/dew28728119448
     [Google Scholar]
  11. HomburgR. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome.Best Pract. Res. Clin. Obstet. Gynaecol.200418577378810.1016/j.bpobgyn.2004.05.00615380146
     [Google Scholar]
  12. WildR.A. CarminaE. Diamanti-KandarakisE. DokrasA. Escobar-MorrealeH.F. FutterweitW. LoboR. NormanR.J. TalbottE. DumesicD.A. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.J. Clin. Endocrinol. Metab.20109552038204910.1210/jc.2009‑272420375205
     [Google Scholar]
  13. WildRA RizzoM CliftonS CarminaE Lipid levels in polycystic ovary syndrome: Systematic review and metaanalysis.Fertil Steril.20119531073-9.e11110.1016/j.fertnstert.2010.12.027
     [Google Scholar]
  14. Steegers-TheunissenR.P.M. WiegelR.E. JansenP.W. LavenJ.S.E. SinclairK.D. Polycystic ovary syndrome: A brain disorder characterized by eating problems originating during puberty and adolescence.Int. J. Mol. Sci.20202121821110.3390/ijms2121821133153014
     [Google Scholar]
  15. CunninghamJ. Infertility.JAAPA2017309192510.1097/01.JAA.0000522130.01619.b728787288
     [Google Scholar]
  16. MeloA.S. FerrianiR.A. NavarroP.A. Treatment of infertility in women with polycystic ovary syndrome: Approach to clinical practice.Clinics2015701176576910.6061/clinics/2015(11)0926602525
     [Google Scholar]
  17. PeckT.J. HibbertK.A. Recent advances in the understanding and management of ARDS.F1000 Res.20198195910.12688/f1000research.20411.131824644
     [Google Scholar]
  18. HawkinsS.M. MatzukM.M. The menstrual cycle: Basic biology.Ann. N. Y. Acad. Sci.200811351101810.1196/annals.1429.01818574203
     [Google Scholar]
  19. YauT.T.L. NgN.Y.H. CheungL.P. MaR.C.W. Polycystic ovary syndrome: A common reproductive syndrome with long-term metabolic consequences.Hong Kong Med. J.201723662263410.12809/hkmj17630829170361
     [Google Scholar]
  20. AliA.I. HassanW.N.M. AlrawiS. A copeptin as a predictor marker for insulin resistance among women with polycystic ovary syndrome.Curr. Womens Health Rev.2022184e08122119867010.2174/1573404817666211208152049
     [Google Scholar]
  21. NdefoU.A. EatonA. GreenM.R. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches.P&T201338633635523946629
     [Google Scholar]
  22. MorleyP. CalaresuF.R. BarbeG.J. ArmstrongD.T. Insulin enhances luteinizing hormone-stimulated steroidogenesis by porcine theca cells.Biol. Reprod.198940473574310.1095/biolreprod40.4.7352473786
     [Google Scholar]
  23. DumesicD.A. OberfieldS.E. Stener-VictorinE. MarshallJ.C. LavenJ.S. LegroR.S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome.Endocr. Rev.201536548752510.1210/er.2015‑101826426951
     [Google Scholar]
  24. JohnsonT. KaplanL. OuyangP. RizzaP. National Institutes of Health. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome.Available from: https://prevention.nih.gov/sites/default/files/2018-06/FinalReport.pdf (Accessed on: February 17).
  25. MumusogluS. YildizB.O. Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population.Curr. Opin. Endocr. Metab. Res.202012667110.1016/j.coemr.2020.03.004
     [Google Scholar]
  26. MartinsW.P. KollmannM. Raine-FenningN. Counting ovarian follicles: Updated threshold for diagnosis of hyperandrogenic anovulation.Ultrasound Obstet. Gynecol.201444213113410.1002/uog.1340225088509
     [Google Scholar]
  27. DewaillyD. LujanM.E. CarminaE. CedarsM.I. LavenJ. NormanR.J. Escobar-MorrealeH.F. Definition and significance of polycystic ovarian morphology: A task force report from the androgen excess and polycystic ovary syndrome society.Hum. Reprod. Update201420333435210.1093/humupd/dmt06124345633
     [Google Scholar]
  28. FraissinetA. RobinG. PignyP. LefebvreT. Catteau-JonardS. DewaillyD. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: Impact on diagnosis and phenotypic classification of polycystic ovary syndrome.Hum. Reprod.20173281716172210.1093/humrep/dex23928854589
     [Google Scholar]
  29. BellverJ. Rodríguez-TaberneroL. RoblesA. MuñozE. MartínezF. LanderasJ. García-VelascoJ. FontesJ. ÁlvarezM. ÁlvarezC. AcevedoB. Polycystic ovary syndrome throughout a woman’s life.J. Assist. Reprod. Genet.2018351253910.1007/s10815‑017‑1047‑728951977
     [Google Scholar]
  30. WitchelS.F. OberfieldS. RosenfieldR.L. CodnerE. BonnyA. IbáñezL. PenaA. HorikawaR. Gomez-LoboV. JoelD. TfayliH. ArslanianS. DabadghaoP. Garcia RudazC. LeeP.A. The diagnosis of polycystic ovary syndrome during adolescence.Horm. Res. Paediatr.201583637638910.1159/00037553025833060
     [Google Scholar]
  31. WestS. LashenH. BloiguA. FranksS. PuukkaK. RuokonenA. JärvelinM.R. TapanainenJ.S. Morin-PapunenL. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study.Hum. Reprod.201429102339235110.1093/humrep/deu20025085801
     [Google Scholar]
  32. EzehU. EzehC. PisarskaM.D. AzzizR. Menstrual dysfunction in polycystic ovary syndrome: Association with dynamic state insulin resistance rather than hyperandrogenism.Fertil. Steril.202111561557156810.1016/j.fertnstert.2020.12.01533602559
     [Google Scholar]
  33. FitzgeraldS. DiVastaA. GoodingH. An update on PCOS in adolescents.Curr. Opin. Pediatr.201830445946510.1097/MOP.000000000000063629782382
     [Google Scholar]
  34. KansraA.R. LakkunarajahS. JayM.S. Childhood and adolescent obesity: A review.Front Pediatr.2021858146110.3389/fped.2020.58146133511092
     [Google Scholar]
  35. SulaimanM. Al-FarsiY. Al-KhaduriM. WalyM. SalehJ. Al-AdawiS. Psychological burden among women with polycystic ovarian syndrome in Oman: A case–control study.Int. J. Womens Health2017989790410.2147/IJWH.S14538329276413
     [Google Scholar]
  36. BurgioS. PolizziC. BuzzaccariniG. LaganàA.S. GulloG. PerriconeG. PerinoA. CucinellaG. AlesiM. Psychological variables in medically assisted reproduction: A systematic review.Przegl. Menopauz.2022211476310.5114/pm.2022.11440435388278
     [Google Scholar]
  37. Veltman-VerhulstS.M. BoivinJ. EijkemansM.J.C. FauserB.J.C.M. Emotional distress is a common risk in women with polycystic ovary syndrome: A systematic review and meta-analysis of 28 studies.Hum. Reprod. Update201218663865110.1093/humupd/dms02922824735
     [Google Scholar]
  38. SinghA. VijayaK. Sai LaxmiK. Prevalence of polycystic ovarian syndrome among adolescent girls: A prospective study.Int. J. Reprod. Contracept. Obstet. Gynecol.20187114375437810.18203/2320‑1770.ijrcog20184230
     [Google Scholar]
  39. TeedeH. DeeksA. MoranL. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.BMC Med.2010814110.1186/1741‑7015‑8‑4120591140
     [Google Scholar]
  40. StrowitzkiT. HalserB. DemantT. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome.Gynecol. Endocrinol.2002161455110.1080/gye.16.1.45.5111915581
     [Google Scholar]
  41. LimS.S. DaviesM.J. NormanR.J. MoranL.J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis.Hum. Reprod. Update201218661863710.1093/humupd/dms03022767467
     [Google Scholar]
  42. KarjulaS. Morin-PapunenL. AuvinenJ. RuokonenA. PuukkaK. FranksS. JärvelinM.R. TapanainenJ.S. JokelainenJ. MiettunenJ. PiltonenT.T. Psychological distress is more prevalent in fertile age and premenopausal women with PCOS symptoms: 15-year follow-up.J. Clin. Endocrinol. Metab.201710261861186910.1210/jc.2016‑386328323926
     [Google Scholar]
  43. JulianLJ Measures of anxiety.Arthritis care & research20116311
     [Google Scholar]
  44. Practice Committee of the American Society for Reproductive MedicineDefinitions of infertility and recurrent pregnancy loss: A committee opinion.Fertil. Steril.20139916310.1016/j.fertnstert.2012.09.02323095139
     [Google Scholar]
  45. StoicescuM. BungăuS.G. ŢiţD.M. MuţiuG. PurzaA.L. IovanV.C. PopO.L. Carcinogenic uterine risk of repeated abortions: Hormone receptors tumoral expression.Rom. J. Morphol. Embryol.20175841429143429556637
     [Google Scholar]
  46. CostelloM.F. MissoM.L. WongJ. HartR. RombautsL. MelderA. NormanR.J. TeedeH.J. The treatment of infertility in polycystic ovary syndrome: A brief update.Aust. N. Z. J. Obstet. Gynaecol.201252440040310.1111/j.1479‑828X.2012.01448.x22639834
     [Google Scholar]
  47. BalenA.H. RutherfordA.J. Managing anovulatory infertility and polycystic ovary syndrome.BMJ2007335762166366610.1136/bmj.39335.462303.8017901517
     [Google Scholar]
  48. SchmidJ. KirchengastS. Vytiska-BinstorferE. HuberJ. Infertility caused by PCOS—health-related quality of life among Austrian and Moslem immigrant women in Austria.Hum. Reprod.200419102251225710.1093/humrep/deh43215333601
     [Google Scholar]
  49. WalkerH.E. Sexual problems and infertility.Psychosomatics197819847748410.1016/S0033‑3182(78)70941‑2693780
     [Google Scholar]
  50. PasqualiR. GambineriA. Role of changes in dietary habits in polycystic ovary syndrome.Reprod. Biomed. Online20048443143910.1016/S1472‑6483(10)60927‑315149567
     [Google Scholar]
  51. HaddonA.C. Obituary Major A. J. N. Tremearne.Folklore191526443143210.1080/0015587X.1915.9718903
     [Google Scholar]
  52. KoperaD. WehrE. Obermayer-PietschB. Endocrinology of hirsutism.Int. J. Trichology201021303510.4103/0974‑7753.6691021188021
     [Google Scholar]
  53. LowensteinE.J. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome.Dermatol. Ther.200619421022310.1111/j.1529‑8019.2006.00077.x17004997
     [Google Scholar]
  54. FerrimanD. GallweyJ.D. Clinical assessment of body hair growth in women.J. Clin. Endocrinol. Metab.196121111440144710.1210/jcem‑21‑11‑144013892577
     [Google Scholar]
  55. XuY. QiaoJ. Association of insulin resistance and elevated androgen levels with Polycystic Ovarian Syndrome (PCOS): A review of literature.J. Healthc. Eng.2022202211310.1155/2022/924056935356614
     [Google Scholar]
  56. AliA.I. NoriW. Correlation of serum visfatin level in non-obese women with polycystic ovary syndrome and matched control.Reprod. Sci.202229113285329310.1007/s43032‑022‑00986‑z35687303
     [Google Scholar]
  57. ToosyS. SodiR. PappachanJ.M. Lean polycystic ovary syndrome (PCOS): An evidence-based practical approach.J. Diabetes Metab. Disord.201817227728510.1007/s40200‑018‑0371‑530918863
     [Google Scholar]
  58. LaaksoM. KuusistoJ. Insulin resistance and hyperglycaemia in cardiovascular disease development.Nat. Rev. Endocrinol.201410529330210.1038/nrendo.2014.2924663222
     [Google Scholar]
  59. AlbertiK.G.M.M. EckelR.H. GrundyS.M. ZimmetP.Z. CleemanJ.I. DonatoK.A. FruchartJ.C. JamesW.P.T. LoriaC.M. SmithS.C.Jr Harmonizing the metabolic syndrome.Circulation2009120161640164510.1161/CIRCULATIONAHA.109.19264419805654
     [Google Scholar]
  60. EhrmannD.A. LiljenquistD.R. KaszaK. AzzizR. LegroR.S. GhazziM.N. PCOS/Troglitazone Study GroupPrevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.J. Clin. Endocrinol. Metab.2006911485310.1210/jc.2005‑132916249284
     [Google Scholar]
  61. ApridonidzeT. EssahP.A. IuornoM.J. NestlerJ.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.J. Clin. Endocrinol. Metab.20059041929193510.1210/jc.2004‑104515623819
     [Google Scholar]
  62. de GrootP.C.M. DekkersO.M. RomijnJ.A. DiebenS.W.M. HelmerhorstF.M. PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis.Hum. Reprod. Update201117449550010.1093/humupd/dmr00121335359
     [Google Scholar]
  63. CarminaE LoboRA Is there really increased cardiovascular morbidity in women with polycystic ovary syndrome?J Women’s Health (2002)2018271113858
     [Google Scholar]
  64. Diamanti-KandarakisE. MitrakouA. RaptisS. TolisG. DulebaA.J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.J. Clin. Endocrinol. Metab.19988382699270510.1210/jcem.83.8.50419709934
     [Google Scholar]
  65. AnagnostisP. TarlatzisB.C. KauffmanR.P. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences.Metabolism201886334310.1016/j.metabol.2017.09.01629024702
     [Google Scholar]
  66. OsibogunO. OgunmorotiO. MichosE.D. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.Trends Cardiovasc. Med.202030739940410.1016/j.tcm.2019.08.01031519403
     [Google Scholar]
  67. GlintborgD. RubinK.H. NyboM. AbrahamsenB. AndersenM. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.Cardiovasc. Diabetol.20181713710.1186/s12933‑018‑0680‑529519249
     [Google Scholar]
  68. ZhaoL. ZhuZ. LouH. ZhuG. HuangW. ZhangS. LiuF. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): A meta-analysis.Oncotarget2016723337153372110.18632/oncotarget.955327220885
     [Google Scholar]
  69. ZhouY. WangX. JiangY. MaH. ChenL. LaiC. PengC. HeC. SunC. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: Insights from a meta-analysis.Gynecol. Endocrinol.2017331290491010.1080/09513590.2017.134777928696807
     [Google Scholar]
  70. AkramW. NoriW. ZghairM.A.G. Area under the curve of carotid artery doppler as a sensitive marker of insulin sensitivity among Iraqi women with polycystic ovarian syndrome: A cross-sectional study.Ital J Gynaecol Obstet.202110.36129/jog.2022.86
     [Google Scholar]
  71. RosenfieldR.L. EhrmannD.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited.Endocr. Rev.201637546752010.1210/er.2015‑110427459230
     [Google Scholar]
  72. LujanM.E. ChizenD.R. PiersonR.A. Diagnostic criteria for polycystic ovary syndrome: Pitfalls and controversies.J. Obstet. Gynaecol. Can.200830867167910.1016/S1701‑2163(16)32915‑218786289
     [Google Scholar]
  73. SzczukoM. KikutJ. SzczukoU. SzydłowskaI. Nawrocka-RutkowskaJ. ZiętekM. VerbanacD. SasoL. Nutrition strategy and life style in polycystic ovary syndrome—narrative review.Nutrients2021137245210.3390/nu1307245234371961
     [Google Scholar]
  74. VesaC.M. PopaL. PopaA.R. RusM. ZahaA.A. BungauS. TitD.M. Corb AronR.A. ZahaD.C. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors.Diagnostics202010531410.3390/diagnostics1005031432429441
     [Google Scholar]
  75. PopaA. FratilaO. RusM. AronR. VesaC. PantisC. DiaconuC. BratuO. BungauS. NemethS. Risk factors for adiposity in the urban population and influence on the prevalence of overweight and obesity.Exp. Ther. Med.202020112913310.3892/etm.2020.866232509005
     [Google Scholar]
  76. GoudasV.T. DumesicD.A. Polycystic ovary syndrome.Endocrinol. Metab. Clin. North Am.199726489391210.1016/S0889‑8529(05)70286‑39429864
     [Google Scholar]
  77. AgrawalN.K. Management of hirsutism.Indian J. Endocrinol. Metab.2013177Suppl. 17710.4103/2230‑8210.11951124251227
     [Google Scholar]
  78. SwigloB.A. CosmaM. FlynnD.N. KurtzD.M. LaBellaM.L. MullanR.J. ErwinP.J. MontoriV.M. Clinical review: Antiandrogens for the treatment of hirsutism: A systematic review and metaanalyses of randomized controlled trials.J. Clin. Endocrinol. Metab.20089341153116010.1210/jc.2007‑243018252786
     [Google Scholar]
  79. PazosF. Escobar-MorrealeH.F. BalsaJ. SanchoJ.M. VarelaC. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.Fertil. Steril.199971112212810.1016/S0015‑0282(98)00414‑29935128
     [Google Scholar]
  80. LiuZ. GengY. HuangY. HuR. LiF. SongY. ZhangM. Letrozole compared with clomiphene citrate for polycystic ovarian syndrome.Obstet. Gynecol.2023141352353410.1097/AOG.000000000000507036735392
     [Google Scholar]
  81. BansalS. GoyalM. SharmaC. ShekharS. Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial.Int. J. Gynaecol. Obstet.2021152334535010.1002/ijgo.1337532920843
     [Google Scholar]
  82. BahawiY.O. RadwanE.M. KhoujM.A. AlotaibiR.K. BajuwaiberN.A. BaghlafL.F. AlFarajW.F. OraifA.M. Pregnancy Rates in Women With Polycystic Ovary Syndrome (PCOS) using letrozole versus clomiphene citrate: A retrospective record review.Cureus2023157e4225710.7759/cureus.4225737605693
     [Google Scholar]
  83. WeissN.S. KostovaE. NahuisM. MolB.W.J. van der VeenF. van WelyM. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.Cochrane Libr.201920191CD01029010.1002/14651858.CD010290.pub330648738
     [Google Scholar]
  84. TataruA.L. FurauG. AfilonJ. IonescuC. DimitriuM. BratuO.G. TitD.M. BungauS. FurauC. The situation of cervical cancers in the context of female genital cancer clustering and burden of disease in Arad County, Romania.J. Clin. Med.2019819610.3390/jcm801009630650666
     [Google Scholar]
  85. EhrmannD.A. BarnesR.B. RosenfieldR.L. CavaghanM.K. ImperialJ. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.Diabetes Care199922114114610.2337/diacare.22.1.14110333916
     [Google Scholar]
  86. CataldoN.A. AbbasiF. McLaughlinT.L. BasinaM. FechnerP.Y. GiudiceL.C. ReavenG.M. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.Hum. Reprod.200621110912010.1093/humrep/dei28916155076
     [Google Scholar]
  87. BrettenthalerN. De GeyterC. HuberP.R. KellerU. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.J. Clin. Endocrinol. Metab.20048983835384010.1210/jc.2003‑03173715292314
     [Google Scholar]
  88. Hemayatkhah-JahromiV. Rahmanian-KoushkakiM. Effect of hydro-alcoholic extract of Aloe vera L. on polycystic ovary syndrome in rat.Feyz201620221227
     [Google Scholar]
  89. KumarR. SharmaB. TomarN.R. RoyP. GuptaA.K. KumarA. In vivo evaluation of hypoglycemic activity of Aloe spp. and identification of its mode of action on GLUT-4 gene expression in vitro.Appl. Biochem. Biotechnol.201116481246125610.1007/s12010‑011‑9210‑621409411
     [Google Scholar]
  90. ArmaniniD. CastelloR. ScaroniC. BonanniG. FacciniG. PellatiD. BertoldoA. FioreC. MoghettiP. Treatment of polycystic ovary syndrome with spironolactone plus licorice.Eur. J. Obstet. Gynecol. Reprod. Biol.20071311616710.1016/j.ejogrb.2006.10.01317113210
     [Google Scholar]
  91. ColdebellaD. BuzzaccariniG. FerrariJ. SleimanZ. D’AlterioM.N. Della CorteL. CucinellaG. GulloG. Inositols administration: further insights on their biological role.Ital. J. Gynaecol. Obstet.2023351303610.36129/jog.2022.40
     [Google Scholar]
  92. LaganàA.S. MontiN. FedeliV. GulloG. BizzarriM. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?Eur. Rev. Med. Pharmacol. Sci.20222641241124735253180
     [Google Scholar]
  93. D GenazzaniA. DespiniG. SantagniS. PratiA. RattighieriE. ChierchiaE. SimonciniT. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS.Endocrinol. Metab. Syndr.20143314010.4172/2161‑1017.1000140
     [Google Scholar]
  94. MenichiniD. ForteG. OrrùB. The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review.Int. J. Vitam. Nutr. Res.20209221833284035
     [Google Scholar]
  95. YangH. KimH.J. PyunB.J. LeeH.W. Licorice ethanol extract improves symptoms of polycytic ovary syndrome in Letrozole-induced female rats.Integr. Med. Res.20187326427010.1016/j.imr.2018.05.00330271715
     [Google Scholar]
  96. NewairyA.S.A. AbdouH.M. Protective role of flax lignans against lead acetate induced oxidative damage and hyperlipidemia in rats.Food Chem. Toxicol.200947481381810.1016/j.fct.2009.01.01219271316
     [Google Scholar]
  97. OsmanN.N. AlsahfiS.A. AlshubailyF. Effectiveness of aqueous extract of fenugreek seeds and flaxseed on polycystic ovarian syndrome in female rats.Int J Pharm Res Allied Sci201984254
     [Google Scholar]
  98. SivasankarapillaiV.S. MadhuK.N.R. RahdarA. BungauS. ZahaD.C. AleyaL. TitD.M. Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera.Environ. Sci. Pollut. Res. Int.20202721260252603510.1007/s11356‑020‑09028‑032405942
     [Google Scholar]
  99. MedenicaS. ZivanovicD. BatkoskaL. MarinelliS. BasileG. PerinoA. CucinellaG. GulloG. ZaamiS. The future is coming: Artificial Intelligence in the treatment of infertility could improve assisted reproduction outcomes—the value of regulatory frameworks.Diagnostics20221212297910.3390/diagnostics1212297936552986
     [Google Scholar]
  100. CowanS. LimS. AlyciaC. PirottaS. ThomsonR. Gibson-HelmM. BlackmoreR. NaderpoorN. BennettC. EeC. RaoV. MousaA. AlesiS. MoranL. Lifestyle management in polycystic ovary syndrome-beyond diet and physical activity.BMC Endocr. Disord.20232311410.1186/s12902‑022‑01208‑y36647089
     [Google Scholar]
  101. MasicI. MiokovicM. MuhamedagicB. Evidence based medicine-new approaches and challenges.Acta Inform. Med.200816421922510.5455/aim.2008.16.219‑22524109156
     [Google Scholar]
/content/journals/cwhr/10.2174/0115734048268656231127064615
Loading
A Complete Overview of the Polycystic Ovarian Syndrome with Recent Advancement in Clinical Trial
Current Women's Health Reviews 21, E160124225716 (2025); https://doi.org/10.2174/0115734048268656231127064615
/content/journals/cwhr/10.2174/0115734048268656231127064615
/content/journals/cwhr/10.2174/0115734048268656231127064615
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): hirsutism; infertility burden; insulin resistance; obesity; PCOS; psychological burden

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test